Tracing the origins of chromosomal translocations in prostate cancer

追踪前列腺癌染色体易位的起源

基本信息

  • 批准号:
    8374150
  • 负责人:
  • 金额:
    $ 11.48万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2012
  • 资助国家:
    美国
  • 起止时间:
    2012-08-15 至 2014-07-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Chromosomal translocations are a hallmark of cancer progression. These translocations often result in gene fusions, a common mechanism for oncogene activation. Until recently, recurrent gene fusions were predominantly associated with hematological malignancies (leukemias and lymphomas) and soft tissue tumors (sarcomas), but were rarely linked to common epithelial carcinomas. This view changed with the discovery of recurrent gene fusions involving ETS family genes in prostate cancer. Among the ETS family gene fusions, the TMPRSS2-ERG fusions involving the 5'untranslated region of androgen-regulated gene TMPRSS2 with the ERG gene are the most common and found in approximately 50% of prostate cancers. The development of next generation sequencing based approaches like RNA-Seq and paired-end whole-genome sequencing have accelerated the discoveries of gene fusions in prostate cancer. However, the mechanisms underlying the formation and cell type specificities of chromosomal translocations are far from clear. Our proposal aims to bridge the gap between the rapid discovery of chromosomal translocations and our limited understanding of the mechanisms leading to their formation. In our recent study, we demonstrate that androgen signaling induces chromosomal proximity between TMPRSS2 and ERG loci, and facilitates the formation of the TMPRSS2-ERG gene fusion when subjected to an agent that causes DNA double strand breaks. These results provide a conceptual framework for the genesis of gene fusions in human prostate cancer. In specific aim 1, we propose to employ next-generation sequencing to identify genome-wide chromosomal interactions mediated by androgen signaling. The mentor's expertise in throughput technologies will help the candidate acquire the necessary skill-set to accomplish aim 1. Interestingly, we identified novel recurrent mutations in the androgen receptor AR collaborating factor FOXA1, which is mutated in 5 of 147 (3.4%) prostate cancers. Preliminary functional studies on one representative mutation revealed that mutated FOXA1 disrupts androgen signaling and increases proliferation. In specific aim 2, we propose to study the effect of FOXA1 mutations in regulating AR signaling and interactome. Aim 2, a logical extension of aim 1 will be pursued during the independent phase (R00). Accomplishment of these two aims will provide us with a comprehensive understanding of the three dimensional genomic architecture of prostatic cells, how AR regulates this architecture, the influence mutations in AR collaborating factors, and importantly how this impacts the formation of gene fusions. While spatial proximity is necessary for chromosomal translocations, it is not sufficient. DNA breaks synergize with spatial proximity to fuel chromosomal translocations. In specific aim 3, we will study the role of inflammation mediated activation of NF-kB pathway in the formation of DNA breaks and ETS gene fusions in prostate cancer. Successful completion of the aims outlined in this proposal will improve our understanding of the origins of chromosomal translocations in prostate cancer, may have broader implications for understanding and treating cancer and may provide suggestions as to the general etiology of human prostate cancer. These projects have been conceived based on my original ideas. Dr. Chinnaiyan has extended his full support towards my career goals and has encouraged me to take these projects to my independent lab in the future. PUBLIC HEALTH RELEVANCE: Chromosomal translocations are a hallmark of cancer progression. However, the mechanisms underlying their formation in cancer tissues are not clear. The central objective of this proposal is to understand the mechanistic basis of chromosomal translocations.
描述(由申请人提供):染色体易位是癌症进展的标志。这些易位通常会导致基因融合,这是癌基因激活的常见机制。直到最近,复发性基因融合主要与血液恶性肿瘤(白血病和淋巴瘤)和软组织肿瘤(肉瘤)相关,但很少与常见的上皮癌相关。随着前列腺癌中涉及 ETS 家族基因的反复基因融合的发现,这种观点发生了变化。在ETS家族基因融合中,涉及雄激素调节基因TMPRSS2的5'非翻译区与ERG基因的TMPRSS2-ERG融合是最常见的,并且在大约50%的前列腺癌中发现。 RNA-Seq 和双端全基因组测序等基于下一代测序的方法的发展加速了前列腺癌基因融合的发现。然而,染色体易位的形成和细胞类型特异性的机制尚不清楚。我们的提议旨在弥合染色体易位的快速发现与我们对导致其形成的机制的有限理解之间的差距。在我们最近的研究中,我们证明雄激素信号传导诱导 TMPRSS2 和 ERG 位点之间的染色体接近,并在受到导致 DNA 双链断裂的试剂时促进 TMPRSS2-ERG 基因融合的形成。这些结果为人类前列腺癌基因融合的发生提供了概念框架。在具体目标 1 中,我们建议采用新一代测序来识别雄激素信号传导介导的全基因组染色体相互作用。导师在吞吐量技术方面的专业知识将帮助候选人获得实现目标 1 所需的技能。有趣的是,我们在雄激素受体 AR 协作因子 FOXA1 中发现了新的复发突变,该因子在 147 例前列腺癌中的 5 例 (3.4%) 中发生突变。对一种代表性突变的初步功能研究表明,突变的 FOXA1 会破坏雄激素信号传导并增加增殖。在具体目标 2 中,我们建议研究 FOXA1 突变在调节 AR 信号传导和相互作用组中的影响。目标 2 是目标 1 的逻辑延伸,将在独立阶段 (R00) 实现。这两个目标的实现将使我们全面了解前列腺细胞的三维基因组结构、AR如何调节这种结构、AR协同因子的影响突变,以及重要的是这如何影响基因融合的形成。虽然空间接近对于染色体易位是必要的,但这还不够。 DNA 断裂与空间邻近性协同作用,促进染色体易位。在具体目标 3 中,我们将研究炎症介导的 NF-kB 通路激活在前列腺癌 DNA 断裂和 ETS 基因融合形成中的作用。成功完成本提案中概述的目标将提高我们对前列腺癌染色体易位起源的理解,可能对理解和治疗癌症产生更广泛的影响,并可能为人类前列腺癌的一般病因学提供建议。这些项目是根据我最初的想法构思的。 Chinnaiyan 博士对我的职业目标给予了全力支持,并鼓励我将来将这些项目带到我的独立实验室。 公共卫生相关性: 染色体易位是癌症进展的标志。然而,它们在癌症组织中形成的机制尚不清楚。该提案的中心目标是了解染色体易位的机制基础。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Ram Shankar Mani其他文献

Functional consequences of novel connexin 26 mutations associated with hereditary hearing loss
与遗传性听力损失相关的新型连接蛋白 26 突变的功能后果
  • DOI:
  • 发表时间:
    2009
  • 期刊:
  • 影响因子:
    5.2
  • 作者:
    Ram Shankar Mani;Aparna Ganapathy;R. Jalvi;C. R. Srikumari Srisailapathy;V. Malhotra;S. Chadha;A. Agarwal;A. Ramesh;Raghunath Rao Rangasayee;A. Anand
  • 通讯作者:
    A. Anand

Ram Shankar Mani的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Ram Shankar Mani', 18)}}的其他基金

3D genome architecture and the origins of recurrent genomic rearrangements in prostate cancer
3D 基因组结构和前列腺癌中反复基因组重排的起源
  • 批准号:
    10092128
  • 财政年份:
    2020
  • 资助金额:
    $ 11.48万
  • 项目类别:
3D genome architecture and the origins of recurrent genomic rearrangements in prostate cancer
3D 基因组结构和前列腺癌中反复基因组重排的起源
  • 批准号:
    10328936
  • 财政年份:
    2020
  • 资助金额:
    $ 11.48万
  • 项目类别:
3D genome architecture and the origins of recurrent genomic rearrangements in prostate cancer
3D 基因组结构和前列腺癌中反复基因组重排的起源
  • 批准号:
    10553609
  • 财政年份:
    2020
  • 资助金额:
    $ 11.48万
  • 项目类别:
Tracing the origins of chromosomal translocations in prostate cancer
追踪前列腺癌染色体易位的起源
  • 批准号:
    8531687
  • 财政年份:
    2012
  • 资助金额:
    $ 11.48万
  • 项目类别:
Tracing the origins of chromosomal translocations in prostate cancer
追踪前列腺癌染色体易位的起源
  • 批准号:
    9204816
  • 财政年份:
    2012
  • 资助金额:
    $ 11.48万
  • 项目类别:
Tracing the origins of chromosomal translocations in prostate cancer
追踪前列腺癌染色体易位的起源
  • 批准号:
    9045579
  • 财政年份:
    2012
  • 资助金额:
    $ 11.48万
  • 项目类别:

相似海外基金

A novel live-attenuated Zika vaccine with a modified 5'UTR
一种带有改良 5UTR 的新型寨卡减毒活疫苗
  • 批准号:
    10730832
  • 财政年份:
    2023
  • 资助金额:
    $ 11.48万
  • 项目类别:
Employing viruses to unravel the functional significance of the m5C epitranscriptome
利用病毒揭示 m5C 表观转录组的功能意义
  • 批准号:
    10638533
  • 财政年份:
    2023
  • 资助金额:
    $ 11.48万
  • 项目类别:
Regulation of RNA sensing and viral restriction by RNA structures
RNA 结构对 RNA 传感和病毒限制的调节
  • 批准号:
    10667802
  • 财政年份:
    2023
  • 资助金额:
    $ 11.48万
  • 项目类别:
Glia Exclusive Gene Therapy
胶质细胞独家基因疗法
  • 批准号:
    10739502
  • 财政年份:
    2023
  • 资助金额:
    $ 11.48万
  • 项目类别:
Muscle-Specific CRISPR/Cas9 Exon Skipping for Duchenne Muscular Dystrophy Therapeutics
肌肉特异性 CRISPR/Cas9 外显子跳跃用于杜氏肌营养不良疗法
  • 批准号:
    10679199
  • 财政年份:
    2023
  • 资助金额:
    $ 11.48万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了